Biohaven Therapeutics Ltd.

This study looked at the long-term safety of the drug BHV-7000 in 233 adults with major depressive disorder. Participants had already completed an earlier study of the drug. The main goal was to track serious side effects, lab changes, and heart rhythm issues. The study did not t…

This study tested a new drug called BHV-2100 for treating migraines quickly. About 647 people with migraines took either the drug or a placebo. The goal was to see if the drug could stop headache pain and other bothersome symptoms within 2 hours.

This study tested a drug called BHV-7000 to see if it safely reduces manic symptoms in people with bipolar I disorder. 274 hospitalized adults took either the drug or a placebo for 21 days. The main goal was to measure changes in mania severity using a standard rating scale.

This study tested a new medication called BHV-7000 in 336 adults with moderate to severe major depression. Participants stopped their usual antidepressants and took either the study drug or a placebo for 6 weeks. The main goal was to see if BHV-7000 reduces depression symptoms be…